David A. Siegel Zentalis Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 101,000 shares of ZNTL stock, worth $413,090. This represents 0.0% of its overall portfolio holdings.

Number of Shares

101,000

Holding current value

$413,090

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $1.09 Million - $1.67 Million	101,000 New	101,000 $1.59 Million
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $661,521 - $1.04 Million	-32,700 Reduced 59.13%	22,600 $490,000
Q2 2022 Aug 15, 2022	SELL	$17.91 - $52.25 $232,830 - $679,250	-13,000 Reduced 19.03%	55,300 $1.55 Million
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $62,370 - $121,335	1,500 Added 2.25%	68,300 $3.15 Million
Q4 2021 Feb 14, 2022	SELL	$66.92 - $84.79 $4.64 Million - $5.88 Million	-69,300 Reduced 50.92%	66,800 $5.62 Million

Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $3.82 Million - $6 Million	81,600 Added 149.72%	136,100 $9.07 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $654,674 - $1.09 Million	17,500 Added 47.3%	54,500 $2.9 Million
Q1 2021 May 17, 2021	BUY	$35.69 - $52.72 $852,991 - $1.26 Million	23,900 Added 182.44%	37,000 $1.61 Million
Q4 2020 Feb 16, 2021	BUY	$31.71 - $57.97 $415,401 - $759,407	13,100 New	13,100 $680,000

Others Institutions Holding ZNTL

# of Institutions

142

Shares Held

76.3M

Call Options Held

68.2K

Put Options Held

2.3K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $233M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account